Drug Trial Radar · NCT02279095
An Open-Label Extension Study of Palovarotene Treatment in Fibrodysplasia Ossificans Progressiva (FOP)
Last checked: Nov 20, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
58
Actual
Start
Oct 9, 2014
Primary completion
Sep 20, 2022
Study completion Sep 20, 2022
Sponsor
- Lead sponsor
- Clementia Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 30, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by heterotopic ossification (HO), i.e., abnormal bone formation, often associated with painful, recurrent episodes of soft tissue swelling (flare-ups). Lesions begin in early childhood and lead to progressive ankyloses of major joints with resultant loss of movement. In this study, the ability of different palovarotene dosing regimens to prevent the formation of new HO will be evaluated in adult and pediatric participants with FOP.
Conditions
- Fibrodysplasia Ossificans Progressiva
Interventions
Palovarotene dose level 1Drug
Palovarotene was taken orally once daily at approximately the same time each day.
Palovarotene dose level 2Drug
Palovarotene will be taken orally once daily at approximately the same time each day.
Palovarotene dose level 3Drug
Palovarotene will be taken orally once daily at approximately the same time each day.
Palovarotene dose level 4Drug
Palovarotene will be taken orally once daily at approximately the same time each day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts A and B: Percentage of Flare-ups With No New Heterotopic Ossification (HO) at Week 12Time frame: Baseline and Week 12
- Parts B and C: Annualized Change in New HO VolumeTime frame: From Baseline (Day 1) up to end of 2 year follow-up period, approximately a maximum of 96 months
Locations
8 sites in 5 countries. Site status is shown where the registry gives one.
University of California San Francisco, Division of Endocrinology and Metabolism
San Francisco, California
Mayo Clinic, Department of Medicine
Rochester, Minnesota
University of Pennsylvania, Center for FOP & Related Bone Disorders
Philadelphia, Pennsylvania
Hospital Italiano de Buenos Aires, Department of Pediatrics
Buenos Aires, Argentina
Royal North Shore Hospital
Saint Leonards, New South Wales, Australia
Queensland University of Technology (QUT) Institute of Health and Biomedical Innovation (IHBI)
Woolloongabba, Queensland, Australia
Hôpital Necker-Enfants Malades, Department of Genetics
Paris, France
The Royal National Orthopaedic Hospital, Brockley Hill
Stanmore, Middlesex, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.